<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994003</url>
  </required_header>
  <id_info>
    <org_study_id>EOC.NSISU.4.12.99</org_study_id>
    <nct_id>NCT03994003</nct_id>
  </id_info>
  <brief_title>BIO-PREDISC-TIA SWISS Cohort Study</brief_title>
  <acronym>PREDISC</acronym>
  <official_title>BIOmarkers and PREDISC Diagnostic Evaluation for Patients With Suspected Transient Ischemic Attacks: the BIOPREDISC- TIA SWISS Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Carlo Cereda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Civico, Lugano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project aims at contributing to improve TIA diagnosis and management by using
      PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A
      swift and accurate TIA diagnosis allows starting treatment of the patient adequately and
      shortly after the event. The shorter the time between the event and treatment onset, the
      better the outcome. This approach will be an important step forward in TIA diagnosis and
      management, similarly to acute coronary syndrome as discussed above.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.</measure>
    <time_frame>1 year</time_frame>
    <description>Diagnostic performance according to PREDISC scale</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cerebrovascular Disease, Ischemic Stroke</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      MiRNA will be isolated from whole blood collected in PAXgene tubes (BD/PreAnalytiX, Franklin
      Lakes, NJ). PAXgene tubes contain an RNA stabilizing reagent that acts at time of blood draw
      to prevent RNA degradation. RNA in whole blood is derived mainly from peripheral blood cells
      (monocytes, neutrophils, T cells, B cells, and megakaryocytes).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected TIA (defined as the acute onset of focal neurological symptoms
        lasting &lt;24 h and presumed to be caused by brain ischemia at the time of referral) within
        48 h of symptoms onset.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected TIA (defined as the acute onset of focal neurological symptoms
             lasting &lt;24 h and presumed to be caused by brain ischemia at the time of referral)
             within 48 h of symptoms onset.

               -  At least 18 years old.

               -  Having given their Informed Consent.

        Exclusion Criteria:

          -  Â· Patients with ocular TIA (Amaurosis fugax).

               -  Patients that still have neurological deficits at the moment of inclusion.

               -  Contraindication to perform MRI.

               -  For women: pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Cereda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurocentro della Svizzera Italiana Ospedale Regionale di Lugano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Cereda, MD</last_name>
    <phone>+41918116691</phone>
    <email>Carlo.Cereda@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Concetta Manno, MD</last_name>
    <phone>+418116454</phone>
    <email>Concetta.Manno@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo W Cereda, MD Ph</last_name>
      <phone>+41918116691</phone>
      <email>carlo.cereda@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jane M Frangi, RN</last_name>
      <phone>+41918116050</phone>
      <email>janemarit.frangi-kultalahti@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Bianco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrik Michel, Prof.</last_name>
      <phone>+41213141185</phone>
      <email>patrik.michel@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ashraf Eskandari</last_name>
      <phone>+41213141265</phone>
      <email>ashraf.eskandari@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Civico, Lugano</investigator_affiliation>
    <investigator_full_name>Dr. med. Carlo Cereda</investigator_full_name>
    <investigator_title>MD Capo Servizio</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

